NCT06551207View on ClinicalTrials.gov

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Fruquintinib

Fruquintinib:5mg ,qd,po, d1-d14, q3w

DRUG

Cadonilimab

Cadonilimab:10mg/kg, ivgtt, d1, q3w

RADIATION

SBRT

SBRT:8-10Gy×5F, god, in 10 days

Trial Locations (1)

430000

RECRUITING

Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Liu Huang

OTHER